Cardiol Therapeutics (CRDL)
(Real Time Quote from BATS)
$2.39 USD
-0.10 (-4.02%)
Updated Jun 7, 2024 11:42 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CRDL 2.39 -0.10(-4.02%)
Will CRDL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRDL
5 Small Drug Stocks to Buy From a Recovering Industry
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Other News for CRDL
Wall Street Analysts Are Bullish on Top Healthcare Picks
Cardiol Therapeutics Sets Annual Shareholders’ Meeting
Cardiol Therapeutics price target raised by $2 at Canaccord, here's why
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024